Mineralys Therapeutics, Inc. (MLYS) insider trading.
In Q3 2026, insiders at Mineralys Therapeutics, Inc. reported 22 non-derivative transactions on 12 Forms 3, 4 and 5: 0 open-market purchases and 11 sales worth $4.7M.
- Transactions
- 22
- Purchases (P)
- 0
- Sales (S)
- 11
- Net shares, P minus S
- -165,497
- Insiders
- 6
- Last filed
- 2026-09-24
Insiders
| Insider | Relationship | Transactions | Buys | Sales |
|---|---|---|---|---|
| Rodman David Malcom | Officer · Chief Medical Officer | 11 | 0 | 5 |
| Warren Eric | Officer · Chief Commercial Officer | 6 | 0 | 3 |
| Karydas Daphne | Director | 2 | 0 | 1 |
| Slingsby Brian Taylor | Director | 1 | 0 | 1 |
| Ferguson James J. III | Officer · Chief Medical Officer | 1 | 0 | 0 |
| Congleton Jon | Director, Officer · Chief Executive Officer | 1 | 0 | 1 |
Transactions
| Date | Insider | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-22 | Slingsby Brian Taylor | S (D) | 104,320 | $28.81 | 7,805,718 | Form 4 |
| 2026-09-21 | Warren Eric | S (D) | 7,438 | $28.12 | 38,400 | Form 4 |
| 2026-09-21 | Warren Eric | M (A) | 7,438 | $13.24 | 45,838 | Form 4 |
| 2026-09-15 | Karydas Daphne | M (A) | 3,000 | $12.02 | 9,200 | Form 4 |
| 2026-09-15 | Karydas Daphne | S (D) | 3,000 | $28.58 | 6,200 | Form 4 |
| 2026-08-21 | Warren Eric | M (A) | 7,437 | $13.24 | 45,837 | Form 4 |
| 2026-08-21 | Warren Eric | S (D) | 7,437 | $25.98 | 38,400 | Form 4 |
| 2026-08-10 | Rodman David Malcom | M (A) | 2,170 | $16 | 53,554 | Form 4 |
| 2026-08-10 | Rodman David Malcom | S (D) | 2,170 | $27.09 | 51,384 | Form 4 |
| 2026-08-10 | Ferguson James J. III | A (A) | 102,400 | $0 | 102,400 | Form 4 |
| 2026-07-21 | Warren Eric | S (D) | 7,438 | $26.87 | 38,400 | Form 4 |
| 2026-07-21 | Warren Eric | M (A) | 7,438 | $13.24 | 45,838 | Form 4 |
| 2026-07-17 | Rodman David Malcom | M (A) | 416 | $15.44 | 51,800 | Form 4 |
| 2026-07-17 | Rodman David Malcom | S (D) | 416 | $26.53 | 51,384 | Form 4 |
| 2026-07-15 | Rodman David Malcom | S (D) | 6,349 | $26.61 | 51,384 | Form 4 |
| 2026-07-13 | Rodman David Malcom | M (A) | 4,167 | $14.25 | 65,442 | Form 4 |
| 2026-07-13 | Rodman David Malcom | S (D) | 14,058 | $27.58 | 57,733 | Form 4 |
| 2026-07-13 | Rodman David Malcom | M (A) | 3,542 | $10.2 | 61,275 | Form 4 |
| 2026-07-13 | Rodman David Malcom | M (A) | 6,349 | $1.08 | 71,791 | Form 4 |
| 2026-07-13 | Congleton Jon | S (D) | 10,700 | $27.24 | 603,621 | Form 4 |
| 2026-07-09 | Rodman David Malcom | M (A) | 2,171 | $16 | 59,904 | Form 4 |
| 2026-07-09 | Rodman David Malcom | S (D) | 2,171 | $30.3 | 57,733 | Form 4 |
Transaction codes in this quarter
Get MLYS insider transactions through the API
curl "https://sec-api.dev/api/v1/insider-transactions?period=2026q3&cik=1933414&limit=100" \
-H "Authorization: Bearer $SEC_API_KEY"Insider trading API guide · MLYS company page · Mineralys Therapeutics, Inc. on SEC.gov
Questions
Are insiders buying or selling Mineralys Therapeutics, Inc. (MLYS)?
In Q3 2026, insiders at Mineralys Therapeutics, Inc. reported 22 non-derivative transactions on 12 Forms 3, 4 and 5: 0 open-market purchases and 11 sales worth $4.7M. Grants, tax withholding and option exercises are counted as transactions but are not purchases or sales.
Where do these Mineralys Therapeutics, Inc. insider trades come from?
From the SEC Insider Transactions Data Sets for Q3 2026, which republish the Forms 3, 4 and 5 filed on EDGAR. Each row links to its filing on SEC.gov.
Plain-text version for agents and LLMs: /insider-trading/mlys.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.